title: Therapeutic plasma exchange performed in parallel with extra corporeal membrane oxygenation for antibody mediated rejection after heart transplantation.
abstract: We report on the feasibility, safety, and efficacy of performing therapeutic plasmapheresis (TPE) in parallel with extracorporeal membrane oxygenation (ECMO) to alleviate antibody mediated rejection (AMR) after heart transplantation. Two pediatric and one adult patient presented with severe congestive heart failure and respiratory distress after heart transplantation and required ECMO support. TPE was initiated to treat AMR while patients remained on ECMO. Each patient received three to five procedures either every day or every other day. One equivalent total plasma volume (TPV) was processed for each procedure (patient TPV + ECMO extracorporeal TPV). A total of 13 TPE procedures were performed with 12 procedures completed without complications or adverse events; one procedure was terminated before completion because of cardiac arrhythmia. Anti-HLA antibody titers decreased after TPE in all three patients. Ventricular function improved and ECMO was discontinued in 2 of 3 patients. Performing large volume TPE with a processed volume up to 2.5 times the patient's TPV is well tolerated in both pediatric (< or = 10 kg) and adult patients. TPE in parallel with ECMO is feasible, safe, and may be measurably effective at reducing anti-HLA antibodies and should be considered as part of the treatment for patients with early AMR after heart transplantation.
authors: Department of Pathology, Columbia University Medical Center, New York, New York 10032, USA. jj222@columbia.edu
authors: Jeffrey
authors: J
authors: Jhang
authors: William
authors: W
authors: Middlesworth
authors: Rose
authors: R
authors: Shaw
authors: Kevin
authors: K
authors: Charette
authors: Joey
authors: J
authors: Papa
authors: Rashida
authors: R
authors: Jefferson
authors: Antonio S
authors: AS
authors: Torloni
authors: Joseph
authors: J
authors: Schwartz
mesh_terms: D000328:Adult; D004062:DiGeorge Syndrome / Q000628:therapy; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D017809:Fatal Outcome; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control / Q000628:therapy*; D006680:HLA Antigens / Q000737:chemistry; D006343:Heart Septal Defects / Q000628:therapy; D016027:Heart Transplantation / Q000379:methods*; D006352:Heart Ventricles / Q000378:metabolism; D006801:Humans; D007223:Infant; D008297:Male; D010100:Oxygen / Q000378:metabolism; D010951:Plasma Exchange / Q000379:methods*
chemical_list: D006680:HLA Antigens; D010100:Oxygen